Danisco US Inc.
Palo Alto, California, United StatesPurpose
To develop a strain producing an engineered anti-RSV (Respiratory Syncytial Virus) antibody used toward developing a large scale, low-cost production system for monoclonal antibodies fit for use in developing countries
Grantee
Division
Global Health
Date
NOVEMBER 2016
Region served
GLOBAL
Committed amount
$3,840,000
Grant topic
Research and Learning Opportunities,
Vaccine Development
Duration (months)
22
Grantee location
Palo Alto, California, United States
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.